Zydus Lifesciences Completes Acquisition of Sterling Biotech API Business
NiveshIQ
NSE: ZYDUSLIFE · Healthcare
Zydus Lifesciences Ltd.
₹1,240.50▼ ₹5.00 (-0.40%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ZYDUSLIFE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Zydus Lifesciences Ltd.
Zydus Lifesciences Limited operates across pharmaceuticals, consumer products, and medical technologies, generating ₹28,592 cr in revenue and ₹4,513 cr net income in the latest fiscal year. The pharma segment drives most earnings through active pharmaceutical ingredients, branded generics, and specialty formulations, while the medical technologies arm focuses on devices and diagnostics. Recent milestones include the launch of the first generic versions of Adempas (Riociguat) in the U.S., expanding its presence in the cardiovascular market and signaling a strategic push into high‑margin specialty drugs. The company’s partnership with MSN Laboratories for U.S. launches underscores its intent to leverage global manufacturing and regulatory expertise. Competitive positioning is strengthened by
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹19,547 Cr +13.40% | ₹23,242 Cr +18.90% | ₹27,148 Cr +16.81% |
| EBITDA Margin | 27.54% | 30.37% | 31.22% |
| Net Profit | ₹3,973 Cr +102.66% | ₹4,673 Cr +17.61% | ₹5,040 Cr +7.86% |
| EPS | ₹38.14 | ₹44.97 | ₹50.09 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Zydus Lifesciences completes acquisition of Sterling Biotech API business
Five Stocks To Buy Today, November 02: Kotak Mahindra Bank, Zydus Lifesciences, Ather Energy, And More
🔒
+ 3 more stories about Zydus Lifesciences Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹8, 017 Cr, PAT ₹990 Cr, EPS ₹9.35, EBITDA margin 25.4%. Growth context: revenue YoY +20.6%, PAT YoY -99.9%, revenue QoQ +5.7%, PAT QoQ -43.1%. Street verdict: miss, revenue surprise +4.3%, PAT surprise -11.0%.
Management commentary points to product launches, approvals, and therapy-mix improvement and order wins, deal pipeline, ...
FY26 (last completed FY): revenue ₹27, 148 Cr, PAT ₹5, 543 Cr, EBITDA margin 33.1%, EPS ₹50.09. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ZYDUSLIFE
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ZYDUSLIFE alongside your other holdings
Unlock full ZYDUSLIFE research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Zydus Lifesciences Ltd.?
NiveshIQ detects active intelligence signals for Zydus Lifesciences Ltd. (ZYDUSLIFE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Zydus Lifesciences Ltd.?
Zydus Lifesciences Ltd. operates in the Healthcare sector with a market capitalisation of ₹11,880,270.4L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.